Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
30.33
+1.41 (4.88%)
Jul 2, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $17.00M in the quarter ending March 31, 2026, a decrease of -39.29%. This brings the company's revenue in the last twelve months to $236.00M, up 67.38% year-over-year. In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%.
Revenue (ttm)
$236.00M
Revenue Growth
+67.38%
P/S Ratio
16.16
Revenue / Employee
$392,679
Employees
601
Market Cap
3.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | 15.00M | 6.65M | 79.58% |
| Dec 31, 2018 | 8.35M | 6.94M | 491.15% |
| Dec 31, 2017 | 1.41M | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Catalyst Pharmaceuticals | 596.96M |
| IDEAYA Biosciences | 225.27M |
| Beam Therapeutics | 164.01M |
| NewAmsterdam Pharma Company | 22.57M |
| Relay Therapeutics | 10.68M |
RCUS News
- 3 days ago - Arcus Biosciences announces publication on ARC-20 study research - TheFly
- 3 days ago - New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan - Business Wire
- 10 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 23 days ago - Arcus Biosciences Transcript: AGM 2026 - Transcripts
- 25 days ago - Arcus Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Arcus Biosciences Slides: FY 2026 - Filings
- 4 weeks ago - Arcus Biosciences initiated with an Outperform at LifeSci Capital - TheFly
- 4 weeks ago - Arcus enters clinical trial collaboration, supply agreement with Bristol Myers - TheFly